Updated Appendix 4C
Filed with ASX · · 5 pages · English
Summary by 6ix AI
The report outlines cash flows from operating activities, including payments for research and development and staff costs, as well as net cash from operating activities. It also details cash flows from investing and financing activities, showing a net cash increase for the period. The compliance statement confirms that the report has been prepared in accordance with accounting standards and provides a true and fair view of the company's cash position.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Biotron
- Agreement with C14 Consulting Group
- $1.8M R&D Rebate Received
- BIT225-012 Phase 2 COVID-19 clinical trial
- BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
- Positive outcomes in BIT225 phase 2 clinical trial in hiv
Later from Biotron
- Renounceable Rights Issue
- Prospectus
- Response to ASX Aware Query
- Supplementary Prospectus
- Response to ASX Query Letter
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron